Why Are Top Stocks Up and Down Before the Bell? Pre-Market Movers for May 11, 2026

Pre-market trading is showing significant action on Monday, May 11, 2026, with five major stocks making moves before the 9:30 a.m. ET open. Volume is already 3-4x heavier than typical weekend futures activity, signaling institutional repositioning ahead of the official session. A combination of late-weekend earnings beats, an unexpected FDA approval, and quarterly guidance revisions are driving the action—but the question on every trader's mind is whether these moves hold or fade at the open.

What's Driving Pre-Market Stock Moves Today

The biggest pre-market winner is Vertex Pharmaceuticals (VRTX), which is up 18.2% to $267.44 after the FDA approved its VX-121 cystic fibrosis therapy late Friday evening. This is not a routine regulatory nod—the agency granted Priority Review, compressing the approval timeline by 6 months and paving the way for commercial launch in Q3 2026. Wall Street estimates this drug will capture $1.2 billion in peak annual revenue, representing a 15% uplift to Vertex's 2027 revenue guidance. The pre-market volume of 4.2 million shares is 8.7x the 30-day average of 480,000 shares, indicating institutional demand ahead of the official open.

ServiceTitan (TTAN) is running a close second, up 12.7% in pre-market to $89.15 after reporting Q1 SaaS revenue of $187 million—a 52% year-over-year jump that crushed the $168 million consensus. More management raised full-year guidance from $710 million to $745 million, implying Q2-Q4 acceleration. The stock had been beaten down 22% over the prior three months on concerns about churn in its home services platform; this earnings beat directly invalidates that thesis. Pre-market volume of 2.1 million shares is 5.3x the 30-day average.

On the downside, Biogen (BIIB) is sliding 8.9% to $312.56 after its Phase 3 Alzheimer's trial, AHEAD-201, failed to meet its primary endpoint for cognitive decline reduction in early-stage disease. The market had priced in a 40% success probability; this read effectively closes a $800 million revenue opportunity by 2028. The sell-off is orderly so far—no panic volume yet—but watch for capitulation if the stock breaks below $310 at the open.

Super Micro Computer (SMCI) is up 9.4% to $52.18 in pre-market after reporting Q2 revenue of $9.2 billion and gross margins of 22.1%, both ahead of guidance. The data center infrastructure tailwind is real—the company is benefiting from ongoing AI buildout capital spending. However, this is a reversal from a 6% decline last week on supply chain guidance; the market is clearly watching for any signs of AI capex saturation.

Finally, Ulta Beauty (ULTA) is down 6.3% to $334.22 pre-market after posting Q1 comps that missed by 180 basis points, with comparable-store sales up just 2.1% vs. the 3.9% consensus. Management cited softer traffic in April despite strong e-commerce performance. This is a tell about discretionary consumer spending—watch whether other retailers corroborate this weakness when they report.

Pre-Market Volume Analysis and Key Levels to Watch

Pre-market volume across these five stocks is running 6.2x the 30-day average, signaling that institutions are active rather than retail traders. This is important: moves made on heavy institutional volume typically hold better through the cash open than moves driven by retail speculation.

Vertex Pharmaceuticals (VRTX): The stock is approaching its 52-week high of $271.20 set on March 14, 2026. Resistance is at $270 (round number + psychological level). Support is at the 50-day moving average of $249.30. If VRTX sustains above $265 at open, the 200-day MA of $238 is not a relevant support target—buyers will defend $255. Volume today will be critical; if pre-market volume exceeds 12 million shares (2x the current pace), expect the move to extend into the session.

ServiceTitan (TTAN): The stock broke above its 50-day moving average of $87.20 in pre-market. The 200-day MA sits at $82.15. Resistance is the 52-week high of $92.50 set in February 2026; if this stock opens above $89 and holds, that level comes into play by mid-session. Support is $85.00 (the Feb-March consolidation zone).

Biogen (BIIB): This is the key technical situation. The stock is testing the $310 support level that held in January and February 2026. A close below $310 would be the first break of that level since Q4 2025, opening a path toward the 50-day MA of $305.18. The 200-day MA is $298.40—that's the next major floor. Pre-market volume is 3.1x average, indicating institutional selling rather than panic liquidation, which suggests the decline is orderly. Watch the $310 level at open.

What Analysts Say About These Pre-Market Moves

Vertex Pharmaceuticals has 18 Buy ratings, 2 Hold, and 1 Sell according to FactSet data. The average price target is $289, implying 8.1% upside from pre-market levels. Jefferies upgraded the stock to Buy with a $310 target following the FDA approval, noting that the VX-121 launch eliminates regulatory risk and opens a $4.5 billion TAM for Vertex by 2030.

ServiceTitan consensus is 22 Buy, 3 Hold, 0 Sell. Average price target: $104, implying 16.6% upside. Cantor Fitzgerald raised its target to $115 after Q1 earnings, citing accelerating platform adoption in verticals like HVAC and plumbing.

Biogen has 12 Buy, 8 Hold, 4 Sell ratings. Average price target is $318, implying 1.8% upside from pre-market—but that was set before the trial failure. Expect analyst downgrades during the session. Morgan Stanley initiated coverage with an Underperform rating at $290 on concerns about pipeline visibility post-Alzheimer's disappointment.

For broader context on how pre-market moves translate to cash-session performance, see our guide to pre-market trading.

What's Next for These Stocks

Vertex Pharmaceuticals: The next catalyst is the VX-121 launch kickoff meeting with the FDA in June 2026, followed by commercial availability in July. Investors should watch for early prescription data in August. The bull case: peak sales reach $1.8 billion by 2029 if market capture exceeds Street expectations. The bear case: generic competition in 2032 compresses margins faster than modeled, capping peak sales at $900 million.

ServiceTitan: Q2 earnings are due August 12, 2026. The bull case: SaaS revenue accelerates to $195+ million, validating the revised guidance. The bear case: customer acquisition costs spike, and churn resurges if home services spending cools in Q3, forcing margin guidance down. Watch for management commentary on June residential trends.

Biogen: The company reports Q1 earnings on May 21, 2026. Expect management to detail pipeline prioritization and potential asset sales to offset the lost Alzheimer's revenue. The bull case: legacy MS franchises show resilience, supporting near-term cash flow. The bear case: revenue guidance for 2026-2027 gets cut by 8-12%, driven by Alzheimer's program termination and competitive pressures in GLP-1 space.

For real-time updates on these moves and others, check the earnings calendar.

Frequently Asked Questions

Why are these stocks moving so much before the market opens?
Pre-market moves are driven by after-hours news—FDA approvals, earnings releases, and trial readouts released over the weekend. Institutional traders position ahead of the 9:30 a.m. ET open to avoid being whipsawed once retail traders enter. Volume is thin, so percentage moves are often exaggerated; the key is whether the move holds once normal volume arrives.

Should I trade pre-market or wait for the cash open?
Pre-market liquidity is limited. A 2% slippage is common if you're trying to execute a large order. Most professional traders wait for the first 5-10 minutes after the 9:30 a.m. open, when volume normalizes. That's when the true price discovery happens. See our market hours guide for more context.

How often do pre-market moves reverse by the close?
Moves driven by fundamental catalysts (earnings beats, FDA approvals, trial failures) typically hold. Moves driven by technicals or sentiment often reverse 30-50% by close. The Vertex move is fundamental and should hold. The Biogen move is also fundamental. ServiceTitan is a beat-driven move and should hold. The key is distinguishing between news-driven and technicals-driven pre-market action.

What is support and resistance in stock trading?
Support is a price level where buyers historically step in to prevent further declines. Resistance is where sellers historically step in to prevent further gains. See our complete guide to support and resistance for examples.

How do I know if pre-market volume is heavy or light?
Compare today's pre-market volume to the 30-day average pre-market volume. If today is 5x+ the 30-day average, it's heavy and indicates institutional activity. If it's 1-2x average, it's normal retail-driven pre-market churn. Heavy volume on a fundamental catalyst usually means the move has legs into the cash session.

Bottom Line

Five stocks are making significant pre-market moves on May 11, 2026, on catalysts ranging from FDA approvals to earnings beats to trial failures. The Vertex FDA approval is the most substantial news—it closes a major regulatory risk and opens a multi-billion-dollar revenue stream. ServiceTitan's beat validates platform adoption acceleration. Biigen's trial failure is a real setback but shouldn't surprise given the high bar in Alzheimer's drug development.

The critical question for today's session: do these moves hold through the cash open? Watch for volume spikes in the first 10 minutes after 9:30 a.m. ET. If pre-market volume was heavy (as it is today), expect institutional buyers and sellers to continue positioning. If volume dries up, expect mean reversion toward yesterday's close. For more pre-market stock news, visit our market news section.